Evidence map›Paper›PMID 26076125›Full record

ArticleBone marrow transplantation2015

Generation of memory T cells for adoptive transfer using clinical-grade anti-CD62L magnetic beads.

S Verfuerth, P S E Sousa, L Beloki, M Murray, M D Peters, A T O'Neill, S Mackinnon, M W Lowdell, R Chakraverty, E R Samuel

Erratum issuedAbstract read
PubMed Publisher
In one paragraph

Article in Bone marrow transplantation, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
0.4field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 11 citations in OpenAlex.

  1. Review
  2. A novel and efficient method to induce allospecific CD8Journal of clinical laboratory analysis · 2021
    Article
  3. Review
  4. Article
  5. CCR7Journal for immunotherapy of cancer · 2017
    Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 2 countries.

S VerfuerthTransplantation Immunology Group, Institute of Cancer Studies, University College London Medical School, Royal Free Campus, London, UK.
P S E SousaTransplantation Immunology Group, Institute of Cancer Studies, University College London Medical School, Royal Free Campus, London, UK.
L BelokiOncohematology Research Group, Navarrabiomed-Miguel Servet Foundation, Pamplona, Spain.
M MurrayThe Centre for Cell, Gene and Tissue Therapeutics, Institute of Immunity and Transplantation, University College London Medical School, Royal Free Campus, London, UK.ORCID http://orcid.org/0000-0002-0379-7161
M D PetersThe Centre for Cell, Gene and Tissue Therapeutics, Institute of Immunity and Transplantation, University College London Medical School, Royal Free Campus, London, UK.
A T O'Neill
S MackinnonDepartment of Haematology, Royal Free London NHS Foundation Trust, London, UK.
M W LowdellThe Centre for Cell, Gene and Tissue Therapeutics, Institute of Immunity and Transplantation, University College London Medical School, Royal Free Campus, London, UK.
R ChakravertyTransplantation Immunology Group, Institute of Cancer Studies, University College London Medical School, Royal Free Campus, London, UK.
E R SamuelThe Centre for Cell, Gene and Tissue Therapeutics, Institute of Immunity and Transplantation, University College London Medical School, Royal Free Campus, London, UK.
The Royal Free Hospital · GBRoyal Free London NHS Foundation Trust · GBNavarrabiomed · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Pre-clinical studies of allogeneic stem cell transplantation suggest that depletion of naive T cells from donor lymphocytes will reduce the risk of GvHD but preserve immunity to infectious pathogens. In this study, we have established a clinical-grade protocol under good manufacturing practice conditions for purging CD62L(+) naive T cells from steady-state leukapheresis products using the CliniMACS system. The efficacy of immunomagnetic CD62L depletion was assessed by analysis of cell composition and functional immune responses. A median 2.9 log CD62L depletion was achieved with no evidence of CD62L shedding during the procedure and a mean T-cell yield of 47%. CD62L(-) cells comprised an equal mix of CD4(+) and CD8(+) T cells, with elimination of B cells but maintenance of regulatory T cells and natural killer cell populations. CD62L-depleted T cells were predominantly CD45RA(-) and CD45RA(+) effector memory (>90%) and contained the bulk of pentamer-staining antivirus-specific T cells. Functional assessment of CD62L(-) cells revealed the maintenance of antiviral T-cell reactivity and a reduction in the alloreactive immune response compared with unmanipulated cells. Clinical-grade depletion of naive T cells using immunomagnetic CD62L beads from steady-state leukapheresis products is highly efficient and generates cells suitable for adoptive transfer in the context of clinical trials.

Indexed as

Adoptive TransferCD8-Positive T-LymphocytesHealthy VolunteersHumansImmunologic MemoryImmunomagnetic Separation

Identifiers

PMID26076125
OpenAlexW4239657568

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.